Halozyme Therapeutics (HALO) Stock Forecast & Price Prediction

Estimation of the future price movement of Halozyme Therapeutics stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.

Price target


Current $39.97

Concensus $61.25


Low $54.00

Median $63.00

High $65.00

Based on analysts projections #HALO is expected to experience a positive growth trajectory over the next year.

The current average HALO price target, as estimated by these analysts, is $61.25.

The predictions for the future HALO stock price range from a low of $54.00 to a high of $65.00, highlighting the variability of market expectations for HALO.

It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.

HALO stock forecasts by analyst

Analyst / firm Date Rating Price target Price when posted
Leerink Partners January 11, 2023 Buy 61.00 55.70
Morgan Stanley December 21, 2022 Buy 65.00 58.63
Wells Fargo November 28, 2022 Buy 65.00 55.54
J.P. Morgan November 22, 2022 Buy 54.00 52.74

Halozyme Therapeutics (HALO) Fundamentals Checker

Financial metrics are used to evaluate financial stability which helps analysts determine if Halozyme Therapeutics is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.

Strong Buy

Financial Scores

Updated on: 07/12/2023

Altman Z-Score: 3.5

Piotroski Score: 7.0

ESG Score

Updated on: 07/12/2023

Environmental: 52.5

Social: 63.8

Governance: 62.6

Financial Health

Updated on: 07/12/2023

DCF: Strong Buy

ROE: Strong Buy

ROA: Neutral

Debt to equity ratio: Strong Buy

Price to earnings ratio: Strong Buy

Price to book ratio: Strong Buy

HALO Discounted Cash Flow

Updated on: 07/12/2023

$40.779
Discounted Cash Flow Value


$39.970
Current Price

HALO Revenues by Segment

Updated on: 07/12/2023

Collaborative Agreements
$1,086,110.00
Development Fees
$590,000.00
Product
$1,910,300.00
Research and Development Services
$96,110.00
Royalty
$3,604,750.00
Sales-based milestone
$100,000.00
Upfront fees
$300,000.00
bulk rHuPH20
$820,840.00

Revenue from Contract with Customer, Excluding Assessed Tax

HALO Revenues by Region

Updated on: 07/12/2023

SWITZERLAND
$1,098,900.00
UNITED STATES
$404,750.00

HALO Notes Due

Updated on: 07/12/2023

CIKExchangeTitle

There are no data to display

Halozyme Therapeutics (HALO) Social Sentiments

Monitoring bullish and bearish sentiments towards Halozyme Therapeutics on Twitter and Stocktwits could help to forecast an upward or downward trend in Halozyme Therapeutics stock price.

No social results for HALO

Rising Prominently: Halozyme Therapeutics' Growth Potential and Stock Forecast

Halozyme Therapeutics (HALO) is an American biotechnology company headquartered in San Diego, California. The company's focus is on developing novel therapies for the treatment of cancer and other chronic diseases by utilizing its proprietary enzyme-based technology platform called Enhanze Technology. Halozyme's Enhanze Technology aims to improve the delivery and efficacy of therapeutic drugs by enabling subcutaneous injection instead of intravenous... Read more

Analyzing Halozyme Therapeutics' Promising Stock Prediction in the Rapidly Growing Biotechnology Sector

Biotechnology is a rapidly growing sector in the stock market, with new technologies and innovations being developed every day to improve human health. The industry is driven by companies that specialize in developing and commercializing drugs, therapies, and medical devices using biotechnology techniques. One such company is Halozyme Therapeutics Inc., listed as HALO in the stock ticker Biotechnology. Halozyme Therapeutics... Read more